FDA Determines Regulatory Review Period for Teslascan Patent Extension Application

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for Teslascan, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to the submission of an application to extend the patent of Teslascan.